Dr. Shah on CAR T-cell Therapy's Effectiveness in ALL

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

Related Content:

Moffitt Cancer CenterOncLive TVCAR T-cell TherapyHematologic Oncology
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC